All data are based on the daily closing price as of November 28, 2025
h
Hanmi Pharm. Co.
128940.KO
310.41 USD
2.96
+0.96%
Overview
Last close
310.41 usd
Market cap
3.94B usd
52 week high
329.98 usd
52 week low
146.58 usd
Target price
301.65 usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
3.948
Price/Book Value
4.8886
Enterprise Value
4.09B usd
EV/Revenue
4.0915
EV/EBITDA
21.9107
Key financials
Revenue TTM
999.12M usd
Gross Profit TTM
551.40M usd
EBITDA TTM
200.24M usd
Earnings per Share
N/A usd
Dividend
0.85 usd
Total assets
1.46B usd
Net debt
243.70M usd
About
Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company's products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). The company has a research collaboration with MEDIC Life Sciences Inc. to identify cancer biomarkers. The company was founded in 1973 and is based in Hwaseong-si, South Korea.